<code id='459778C718'></code><style id='459778C718'></style>
    • <acronym id='459778C718'></acronym>
      <center id='459778C718'><center id='459778C718'><tfoot id='459778C718'></tfoot></center><abbr id='459778C718'><dir id='459778C718'><tfoot id='459778C718'></tfoot><noframes id='459778C718'>

    • <optgroup id='459778C718'><strike id='459778C718'><sup id='459778C718'></sup></strike><code id='459778C718'></code></optgroup>
        1. <b id='459778C718'><label id='459778C718'><select id='459778C718'><dt id='459778C718'><span id='459778C718'></span></dt></select></label></b><u id='459778C718'></u>
          <i id='459778C718'><strike id='459778C718'><tt id='459778C718'><pre id='459778C718'></pre></tt></strike></i>

          
          WSS
          Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT
          Adobe

          In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

          Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

          advertisement

          Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

          For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge